Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study

BACKGROUND: Major depressive disorder (MDD) is the leading cause of disability worldwide. Response to pharmacologic treatment is generally evaluated by traditional clinician- and patient-reported rating scales. Assessing therapeutic efficacy using the Goal Attainment Scale offers a complementary mea...

Descripción completa

Detalles Bibliográficos
Autores principales: McCue, Maggie, Sarkey, Sara, Eramo, Anna, François, Clement, Parikh, Sagar V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665619/
https://www.ncbi.nlm.nih.gov/pubmed/34895181
http://dx.doi.org/10.1186/s12888-021-03608-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665619/
https://www.ncbi.nlm.nih.gov/pubmed/34895181
http://dx.doi.org/10.1186/s12888-021-03608-1

Ejemplares similares